Generex Biotechnology is a drug research and development company whose expertise is finding innovative and commercialized ways to administer drugs throughout the human body. The company has developed a platform technology for the delivery of drugs via the oral cavity.
To meet the demands of this type of drug administration, Generex developed its RapidMist™ device so that the drugs typically administered by injection can be absorbed into the body by the lining of the inner mouth. Combined with Generex’s proprietary liquid drug formulations, the company is able to achieve its goal of innovative drug administration.
Generex’s flagship product, oral insulin (Generex Oral-lyn™), is in various stages of clinical development around the world. The company announced that the global Phase III clinical trial of Generex Oral-lyn™ has commenced in the USA, Canada, Russia, The Ukraine, Romania, Bulgaria and Poland. The product is currently available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and was approved for sale in India in October 2007.
Generex also has a wholly owned subsidiary, Antigen Express, Inc., which uses immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.
Let us hear your thoughts: Generex Biotechnology Corp. Message Board